Drug Profile
EB 02
Alternative Names: EB02Latest Information Update: 13 Oct 2022
Price :
$50
*
At a glance
- Originator Edesa Biotech
- Class Antihaemorrhagics; Nonsteroidal anti-inflammatories
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Haemorrhoids
Most Recent Events
- 13 Oct 2022 Phase-II clinical trials in Haemorrhoids in Canada (Topical) prior to October 2022 (Edesa Biotech pipeline, October 2022)
- 22 Mar 2021 Edesa Biotech in-licenses a non-steroidal anti-inflammatory technology from Hebrew University of Jerusalem
- 13 Feb 2020 Edesa Biotech plans a proof-of-concept clinical trial for Haemorrhoids later in 2020